TenNor and Janssen to Collaborate on Lung Disease Treatments
January 18, 2021 at 04:41 AM EST
TenNor Therapeutics ( Suzhou ) announced a research collaboration with Janssen Pharma that will use TenNor's drug conjugation platform to discover new therapies for the treatment of nontuberculous mycobacteria (NTM) diseases. NTM diseases require treatment by multiple antibiotics administered for a duration of more than two years. Existing therapies are not always effective and may cause side effects. The goal of the collaboration is to discover novel therapies for NTM diseases that shorten the duration of treatment with a better safety and efficacy profile. More details.... Share this with colleagues: // //